Transcriptomics

Dataset Information

0

Molecular Signatures of CB-6644 inhibition of the RUVBL1/2 complex in Multiple Myeloma [RNA-seq]


ABSTRACT: Multiple Myeloma is the second most hematological cancer. RUVBL1 and RUVBL2 forms a subcomplex of many chromatin remodeling complexes implicated in cancer progress. As an inhibitor specific to the RUVBL1/2 complex, CB-6644 exhibits remarkable anti-tumor activity in xenograft models of Burkitt’s lymphoma and multiple myeloma (MM). In this work, we defined transcriptional signatures corresponding to CB-6644 treatment in MM cells and determined underlying epigenetic changes in terms of chromatin accessibility.CB-6644 upregulated biological processes related to interferon response and downregulated those linked to cell proliferation in MM cells. Transcriptional regulator inference identified ATF4/CEBP and E2Fs as regulators for downregulated genes and MED1 and MYC as regulators for upregulated genes. CB-6644-induced changes in chromatin accessibility occurred mostly in non-promoter regions. Footprinting analysis identified transcription factors implied in modulating chromatin accessibility in response to CB-6644 treatment, including ATF4/CEBP and IRF4. Lastly, integrative analysis of transcription responses to various chemical compounds of the molecular signature genes from public gene expression data identified CB-5083, a p97 inhibitor, as a synergistic candidate with CB66-44 in MM cells, but experimental validation refuted this hypothesis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE271840 | GEO | 2024/08/19

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-08-19 | GSE271838 | GEO
2017-10-26 | GSE101923 | GEO
2024-08-31 | E-MTAB-13137 | biostudies-arrayexpress
2023-10-18 | GSE201778 | GEO
2015-11-09 | E-GEOD-73588 | biostudies-arrayexpress
2018-11-02 | E-MTAB-7328 | biostudies-arrayexpress
| PRJNA1133720 | ENA
| PRJNA1133724 | ENA
2019-12-18 | GSE107637 | GEO
2023-03-27 | GSE182378 | GEO